Veracyte (NASDAQ: VCYT) revenue
Veracyte reported revenue of $517.1m for fiscal 2025, 16.0% more than in fiscal 2024 ($445.8m). Since fiscal 2016 its revenue has grown by 694.6%, an average growth of 25.9% a year.
Veracyte has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2020, −2.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $517.1m | +16.0% | $57.8m | 11.2% |
| 2024 | $445.8m | +23.5% | $16.1m | 3.6% |
| 2023 | $361.1m | +21.8% | −$85.8m | −23.8% |
| 2022 | $296.5m | +35.1% | −$41.1m | −13.9% |
| 2021 | $219.5m | +86.8% | −$81.9m | −37.3% |
| 2020 | $117.5m | −2.4% | −$35.4m | −30.1% |
| 2019 | $120.4m | +30.8% | −$15.1m | −12.6% |
| 2018 | $92.0m | +27.9% | −$22.2m | −24.2% |
| 2017 | $72.0m | +10.6% | −$26.5m | −36.9% |
| 2016 | $65.1m | — | −$28.8m | −44.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Veracyte revenue compared with its sector
By revenue for its latest fiscal year, Veracyte ranks 190th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Veracyte, 16.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 188th | AtriCure | $534.5m | 14.9% |
| 189th | Mirum Pharmaceuticals | $521.3m | 54.7% |
| 190th | Veracyte | $517.1m | 16.0% |
| 191st | ADMA Biologics | $510.2m | 19.6% |
| 192nd | Glaukos | $507.4m | 32.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Veracyte
- How much revenue did Veracyte make in fiscal 2025?
- Veracyte reported revenue of $517.1m for fiscal 2025, compared with $445.8m in fiscal 2024.
- How much has the revenue of Veracyte grown?
- Between fiscal 2016 and fiscal 2025 it went from $65.1m to $517.1m: 694.6% more, an average growth of 25.9% a year.
- What was the best year for revenue at Veracyte?
- Of its last 10 fiscal years, fiscal 2025, with $517.1m.
- Where does Veracyte rank in its sector by revenue?
- It ranks 190th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Veracyte come from?
- From the annual report (Form 10-K) that Veracyte files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Veracyte files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Veracyte: the Veracyte page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.